The prognostic and predictive impact of circulating tumour DNA (ctDNA) dynamics in patients with metastatic Triple Negative Breast Cancer (TNBC) on olaparib based therapy: Results from Cohort E of the PlasmaMATCH trial

被引：0
|
作者：
Browne, Iseult
Pascual, Javier
Cutts, Rosalind
Kingston, Belinda
Hrebien, Sarah
Kilburn, Lucy
Pearson, Alex
Moretti, Laura
Wardley, Andrew
Macpherson, Iain
Baird, Richard
Roylance, Rebecca
Faull, Iris
Banks, Kimberly C.
Garcia-Murillas, Isaac
Bliss, Judith
Ring, Alistair
Turner, Nicholas
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PS06-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS06-04
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Results from plasmaMATCH trial cohort E: A phase II trial of olaparib and ceralasertib in patients with triple-negative advanced breast cancer (CRUK/15/010).
    Ring, Alistair E.
    Moretti, Laura
    Afshari-Mehr, Angelica
    Wardley, Andrew M.
    Kilburn, Lucy
    Gurel, Bora
    MacPherson, Iain R.
    Baird, Richard D.
    Martin, Sue
    Pearson, Alex
    Roylance, Rebecca
    Winter, Matthew
    Dunne, Kathryn
    Copson, Ellen
    Hickish, Tamas
    Stephens, Peter
    Burcombe, Russell J.
    Randle, Katrina
    Bliss, Judith
    Turner, Nicholas C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)
    Ring, Alistair
    Kilburn, Lucy S.
    Pearson, Alex
    Moretti, Laura
    Afshari-Mehr, Angelica
    Wardley, Andrew M.
    Gurel, Bora
    Macpherson, Iain R.
    Riisnaes, Ruth
    Baird, Richard D.
    Martin, Sue
    Roylance, Rebecca
    Johnson, Hannah
    Ferreira, Ana
    Winter, Matthew C.
    Dunne, Kathryn
    Copson, Ellen
    Hickish, Tamas
    Burcombe, Russell
    Randle, Kat
    Serra, Violeta
    Llop-Guevara, Alba
    Bliss, Judith M.
    Turner, Nicolas C.
    CLINICAL CANCER RESEARCH, 2023, 29 (23) : 4751 - 4759
  • [3] Assessment of early ctDNA dynamics to predict efficacy of targeted therapies in metastatic breast cancer: Results from plasmaMATCH trial
    Pascual, Javier
    Cutts, Rosalind J.
    Kingston, Belinda
    Hrebien, Sarah
    Kilburn, Lucy S.
    Kernaghan, Sarah
    Moretti, Laura
    Wilkinson, Katie
    Wardley, Andrew M.
    Macpherson, Iain R.
    Baird, Richard D.
    Roylance, Rebecca
    Hubank, Michael
    Walsh, Giselle
    Faull, Iris
    Banks, Kimberly C.
    Lanman, Richard B.
    Garcia-Murillas, Isaac
    Bliss, Judith M.
    Ring, Alistair
    Turner, Nicholas C.
    CANCER RESEARCH, 2021, 81 (04)
  • [4] Circulating Tumour DNA (ctDNA) Detection and Dynamics in Patients with Early Breast Cancer (EBC): Results of the Neoadjuvant TRACER cohort
    Elliott, Mitchell J.
    Veitch, Zachary
    Bedard, Philippe
    Amir, Eitan
    Dou, Aaron
    Antras, Jesus Fuentes
    Nadler, Michelle
    Meti, Nicholas
    Gregorio, Nancy
    Shah, Elizabeth
    Chow, Helen
    Campbell, Nathan
    Terrell, Samantha
    Knape, Charlene
    Howarth, Karen
    Siu, Lillian
    Berman, Hal
    Cescon, David W.
    CANCER RESEARCH, 2023, 83 (05)
  • [5] Predictive and prognostic value of circulating tumor DNA (ctDNA) compared to circulating tumor cells (CTC) in a prospective cohort of metastatic breast cancer patients: The UCBG COMET trial
    Pierga, Jean-Yves
    Silveira, Amanda
    Girard, Elodie
    Lorgis, Veronique
    Tanguy, Marie-Laure
    Albaud, Benoit
    Tredan, Olivier
    Dubot, Coraline
    Hego, Caroline
    Jacot, William
    Goncalves, Anthony
    Debled, Marc
    Levy, Christelle
    Ferrero, Jean-Marc
    Jouannaud, Christelle
    Mouret-Reynier, Marie-Ange
    Dalenc, Florence
    Baulande, Sylvain
    Lemonnier, Jerome
    Berger, Frederique
    Bidard, Francois-Clement
    Proudhon, Charlotte
    CANCER RESEARCH, 2020, 80 (16)
  • [6] Use of Circulating Tumor DNA (ctDNA) for Early Molecular Detection of Breast Cancer Relapse in Patients with Triple-Negative Breast Cancer (TNBC)
    Bagegni, Nusayba A.
    Ademuyiwa, Foluso O.
    CURRENT BREAST CANCER REPORTS, 2023, 15 (04) : 356 - 363
  • [7] Use of Circulating Tumor DNA (ctDNA) for Early Molecular Detection of Breast Cancer Relapse in Patients with Triple-Negative Breast Cancer (TNBC)
    Nusayba A. Bagegni
    Foluso O. Ademuyiwa
    Current Breast Cancer Reports, 2023, 15 : 356 - 363
  • [8] Comparison of genotyping results from tissue and circulating DNA (ctDNA) in patients with metastatic breast cancer
    Malvarosa, G.
    Spring, L.
    Juric, D.
    Moy, B.
    Bardia, A.
    CANCER RESEARCH, 2017, 77
  • [9] Results from plasmaMATCH: a multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer
    Ring, Alistair
    Kingston, Belinda
    Kilburn, Lucy
    Kernaghan, Sarah
    Wardley, Andrew M.
    Macpherson, Iain
    Baird, Richard D.
    Roylance, Rebecca
    Stephens, Peter
    Oikonomidou, Olga
    Braybrooke, Jeremy P.
    Tuthill, Mark
    Abraham, Jacinta
    Winter, Matthew C.
    Bye, Hannah
    Hubank, Michael
    Snowdon, Claire
    Rea, Daniel
    Cameron, David
    Shaaban, Abeer
    Randle, Katrina
    Wilkinson, Katie
    Moretti, Laura
    Bliss, Judith M.
    Turner, Nicholas
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 531 - 531
  • [10] A phase I/II trial of olaparib in combination with eribulin in patients with advanced or metastatic triple negative breast cancer (TNBC) previously treated with anthracyclines and taxanes: First results from phase I
    Yasojima, Hiroyuki
    Yamamoto, Harukaze
    Masuda, Norikazu
    Aogi, Kenjiro
    Takahashi, Masato
    Yonemori, Kan
    Takeuchi, Masahiro
    Hamada, Akinobu
    Tamura, Kenji
    Sukigara, Tamie
    Nagasaka, Ritsuko
    Nakano, Rie
    Tsujimoto, Yukie
    Morioka, Yuka
    Higuchi, Kiyomi
    Fujiwara, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345